Progesterone receptor antagonist dosage form
AssigneeBayer Pharma Aktiengesellschaft
InventorsBarbara SCHUETT, Marcus-Hillert SCHULTZE-MOSGAU, Andreas KAISER
Life of this patent
Estimating the term…
Abstract
The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one at the dosage of about 0.5 to 5 mg and more particularly 2 mg. Additionally, the invention is directed to the use of the novel pharmaceutical composition for treatment of and/or prophylaxis of gynaecological diseases, such as fibroids of the uterus (myomas, uterine leiomyoma), endometriosis or excessive menstrual bleeds, and method for obtaining such composition and oral dosage form.
Claims5
A method of treatment and/or prophylaxis of fibroids of the uterus comprising orally administering, to a woman in need thereof, 2 mg of (11β,17β)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17 (pentafluoroethyl)estra-4,9-dien-3-one of formula
- or a salt thereof.
Dependencies are inferred from the claim text.